Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but introduce non-trivial drug design parameters that must be considered as part of target selection and…
Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window for a promising therapy due to toxicity in non-target tissues. Bispecific drugs engineered to bind…
Our Early Phase Clinical Development solutions provide expert support at every stage, from Candidate Selection through Phase 1.
Certara client forums in China, Korea, and Japan support collaboration and networking among drug developers using model-informed drug development approaches to bring new treatments to patients faster. RADNOR, PA –…
The article from the European Journal of Pharmaceutical Sciences reviews the role of Physiologically Based Pharmacokinetic (PBPK) modeling in the FDA’s approval of novel drugs from 2019 to 2023. It…
Every year, the Consortium—comprising over 30 leading biopharmaceutical companies—convenes to discuss Physiologically Based Pharmacokinetic (PBPK) initiatives in drug development and their regulatory impacts. Consortium members collaborate closely with Simcyp scientists,…
© 2025 Certara. All Rights Reserved. | Privacy policy
